Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DVYA | 52.55 | -0.02 | -0.04% |
| iShares Asia/Pacific Dividend ETF | |||
| FMAR | 53.54 | -0.03 | -0.06% |
| FT Vest US Equity Buffer ETF Mar | |||
| ATTR | 95.47 | -0.10 | -0.11% |
| Arin Tactical Tail Risk ETF | |||
| ROE | 43.52 | -0.10 | -0.23% |
| Astoria US Equal Weight Quality KingsETF | |||
| TESL | 13.59 | -0.86 | -5.93% |
| Simplify Volt TSLA Revolution ETF | |||
A.I.dvisor tells us that ALMS and ZNTL have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALMS and ZNTL's prices will move in lockstep.
| Ticker / NAME | Correlation To ALMS | 1D Price Change % | ||
|---|---|---|---|---|
| ALMS | 100% | -2.29% | ||
| ZNTL - ALMS | 33% Poorly correlated | -2.92% | ||
| MRNA - ALMS | 30% Poorly correlated | -2.23% | ||
| VKTX - ALMS | 27% Poorly correlated | +2.62% | ||
| SNDX - ALMS | 27% Poorly correlated | -0.58% | ||
| DRUG - ALMS | 27% Poorly correlated | -4.20% | ||
More | ||||
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in of 128 cases, the price rose further within the following month. The odds of a continued upward trend are .
ALMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALMS as a result. In of 36 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ALMS moved below its 50-day moving average on August 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALMS crossed bearishly below the 50-day moving average on August 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ALMS entered a downward trend on September 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.178) is normal, around the industry mean (20.572). P/E Ratio (0.166) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (172.414) is also within normal values, averaging (444.169).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ALMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.